After Hours
$
253.50
Change
0.00 0.00%
Volume
Volume 118,939
Jan 22, 2021, 7:26 p.m.
Quotes are delayed by 20 min
Previous close
$ 252.03
$ 253.50
Change
+1.47 +0.58%
Day low
Day high
$250.56
$255.23

52 week low
52 week high
$177.05
$264.97

Market cap
$146.72B
Average volume
2.46M
P/E ratio
20.45
Rev. per Employee
$994,060
EPS
12.40
Dividend
1.76
Div yield
2.78%
Ex dividend date
2/11/21
MarketWatch News on AMGN
-
Dow's 81-point climb led by gains for American Express, Boeing stocks
- MarketWatch Automation
-
Welcome to the Roaring ’20s, but Maybe Not for Stocks, Our Experts Say
- Lauren R. Rublin
-
Illumina CEO Says Business Is Bouncing Back
- Bill Alpert
-
Dow flat despite gains for Coca-Cola, McDonald's shares
- MarketWatch Automation
-
These 6 Dividend Payers Look Primed for Growth in Earnings—and Payouts
- Lawrence C. Strauss
-
These are the best-performing Nasdaq and S&P 500 stocks of 2020
- Philip van Doorn
-
How the Dow Industrials Trailed the S&P 500 in 2020
- Andrew Bary
-
The Dow Fell 68 Points Because Stocks Needed a Breather
- Jacob Sonenshine
-
Dow flat despite gains for shares of Amgen Inc., Boeing
- MarketWatch Automation
-
Boeing, Walgreens Boots share gains contribute to Dow's 130-point jump
- MarketWatch Automation
-
What’s Ahead for Amgen Stock Next Year
- Bill Alpert
-
Walgreens Boots, Amgen Inc. share losses contribute to Dow's nearly 200-point fall
- MarketWatch Automation
-
Goldman Sachs, Amgen Inc. share losses lead Dow's 100-point drop
- MarketWatch Automation
-
Amgen Inc., Goldman Sachs share losses contribute to Dow's 184-point drop
- MarketWatch Automation
-
Dow's 100-point drop led by losses for shares of Amgen Inc., Nike
- MarketWatch Automation
-
Intel, IBM share losses contribute to Dow's nearly 325-point fall
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Analysts’ Latest Recommendations on Mylan
- MarketRealist.com
-
Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
- MarketRealist.com
Other News on AMGN
-
3 Buffett-Munger Stocks Expected to Show Strong Growth
- GuruFocus.com
-
Raymond James Maintains a Hold Rating on Amgen (AMGN)
- SmarterAnalyst
-
Distillate Capital Partners 2020 Year-End Letter To Investors
- Seeking Alpha
-
The 7 Best Healthcare Stocks to Buy for 2021
- InvestorPlace.com
-
Motorhome Retirement: Amgen - Wait For A Better Price
- Seeking Alpha
-
Invest Like A Billionaire With High Yield: THW
- Seeking Alpha
-
DIA: Time For The Dow To Shine This Year
- Seeking Alpha
-
Amgen (AMGN) Receives a Buy from Oppenheimer
- SmarterAnalyst
-
Dividend Growth Pharmaceuticals For 2021
- Seeking Alpha
-
Wall Street Breakfast: The Week Ahead
- Seeking Alpha
-
Dividend Income Update December 2020
- Seeking Alpha
-
HQH: An Overweight Biotech Fund, Paying 8%+ Distribution
- Seeking Alpha
- Loading more headlines...
Earnings Announcement
Press Releases on AMGN
-
Osteoporosis Drugs Market Expected To Boost During 2021 To 2022
- Heraldkeepers
-
Gene Delivery Systems Market By Development, Trends, Investigation 2020 And Forecast To 2026
- Market Insight Reports
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com